Neural Stem Cell-based Regenerative Therapy: A New Approach to Diabetes Treatment.

IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Endocrine, metabolic & immune disorders drug targets Pub Date : 2024-01-01 DOI:10.2174/1871530323666230512121416
Kajal Sharma, Nidhi Puranik, Dhananjay Yadav
{"title":"Neural Stem Cell-based Regenerative Therapy: A New Approach to Diabetes Treatment.","authors":"Kajal Sharma, Nidhi Puranik, Dhananjay Yadav","doi":"10.2174/1871530323666230512121416","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetes mellitus (DM) is the most common metabolic disorder that occurs due to the loss, or impaired function of insulin-secreting pancreatic beta cells, which are of two types - type 1 (T1D) and type 2 (T2D). To cure DM, the replacement of the destroyed pancreatic beta cells of islet of Langerhans is the most widely practiced treatment. For this, isolating neuronal stem cells and cultivating them as a source of renewable beta cells is a significant breakthrough in medicine. The functions, growth, and gene expression of insulin-producing pancreatic beta cells and neurons are very similar in many ways. A diabetic patient's neural stem cells (obtained from the hippocampus and olfactory bulb) can be used as a replacement source of beta cells for regenerative therapy to treat diabetes. The same protocol used to create functional neurons from progenitor cells can be used to create beta cells. Recent research suggests that replacing lost pancreatic beta cells with autologous transplantation of insulin-producing neural progenitor cells may be a perfect therapeutic strategy for diabetes, allowing for a safe and normal restoration of function and a reduction in potential risks and a long-term cure.</p>","PeriodicalId":11614,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871530323666230512121416","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetes mellitus (DM) is the most common metabolic disorder that occurs due to the loss, or impaired function of insulin-secreting pancreatic beta cells, which are of two types - type 1 (T1D) and type 2 (T2D). To cure DM, the replacement of the destroyed pancreatic beta cells of islet of Langerhans is the most widely practiced treatment. For this, isolating neuronal stem cells and cultivating them as a source of renewable beta cells is a significant breakthrough in medicine. The functions, growth, and gene expression of insulin-producing pancreatic beta cells and neurons are very similar in many ways. A diabetic patient's neural stem cells (obtained from the hippocampus and olfactory bulb) can be used as a replacement source of beta cells for regenerative therapy to treat diabetes. The same protocol used to create functional neurons from progenitor cells can be used to create beta cells. Recent research suggests that replacing lost pancreatic beta cells with autologous transplantation of insulin-producing neural progenitor cells may be a perfect therapeutic strategy for diabetes, allowing for a safe and normal restoration of function and a reduction in potential risks and a long-term cure.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于神经干细胞的再生疗法:糖尿病治疗的新方法。
糖尿病(DM)是最常见的代谢性疾病,是由于分泌胰岛素的胰岛β细胞丧失或功能受损引起的,分为 1 型(T1D)和 2 型(T2D)两种。要治愈糖尿病,最广泛采用的治疗方法是替换被破坏的朗格汉斯胰岛的胰岛β细胞。为此,分离神经元干细胞并将其作为可再生β细胞的来源进行培养,是医学上的一项重大突破。产生胰岛素的胰岛β细胞和神经元的功能、生长和基因表达在许多方面都非常相似。糖尿病患者的神经干细胞(取自海马和嗅球)可用作治疗糖尿病的再生疗法的β细胞替代源。用祖细胞制造功能神经元的相同方案也可用于制造β细胞。最近的研究表明,通过自体移植产生胰岛素的神经祖细胞来替代失去的胰岛β细胞,可能是治疗糖尿病的完美策略,可以安全、正常地恢复功能,降低潜在风险并实现长期治愈。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Endocrine, metabolic & immune disorders drug targets
Endocrine, metabolic & immune disorders drug targets ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY
CiteScore
4.60
自引率
5.30%
发文量
217
期刊介绍: Aims & Scope This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.
期刊最新文献
Single-Cell RNA Sequencing Reveals Transcriptional Signatures and Cell-Cell Communication in Diabetic Retinopathy Current Developments in the Prevention and Improvement of Intestinal Disorders: A Mini-Review Clinical Presentation, Diagnosis, and Management of Hyperinsulinemic Hypoglycemia in Adults: A Single-center Experience Attitudes and Acceptance of the Palestinian Population towards COVID-19 Health Precautions and Vaccinations: A Cross-Sectional Study. Diabulimia and Type 1 Diabetes: An Unknown and Emerging Problem
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1